Aberdeen Group plc Has $9.01 Million Position in Twist Bioscience Corporation $TWST

Aberdeen Group plc boosted its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 98.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 320,283 shares of the company’s stock after purchasing an additional 158,879 shares during the period. Aberdeen Group plc owned about 0.53% of Twist Bioscience worth $9,013,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Royal Bank of Canada boosted its stake in Twist Bioscience by 11.8% in the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after buying an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after acquiring an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after acquiring an additional 37,577 shares in the last quarter. Intech Investment Management LLC lifted its holdings in shares of Twist Bioscience by 18.9% in the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after acquiring an additional 4,591 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Twist Bioscience by 8.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock valued at $222,000 after purchasing an additional 469 shares in the last quarter.

Insiders Place Their Bets

In other Twist Bioscience news, Director Jan Johannessen sold 2,200 shares of Twist Bioscience stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $47.91, for a total transaction of $105,402.00. Following the transaction, the director directly owned 17,754 shares of the company’s stock, valued at $850,594.14. The trade was a 11.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dennis Cho sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total transaction of $249,650.00. Following the sale, the insider owned 138,581 shares of the company’s stock, valued at $6,919,349.33. This represents a 3.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 36,609 shares of company stock valued at $1,665,151. Insiders own 3.08% of the company’s stock.

Twist Bioscience Trading Down 4.4%

Shares of TWST stock opened at $52.49 on Friday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $57.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The stock’s fifty day moving average is $40.24 and its two-hundred day moving average is $32.99. The firm has a market capitalization of $3.22 billion, a P/E ratio of -41.01 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company’s revenue for the quarter was up 16.9% compared to the same quarter last year. Research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Evercore upped their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Barclays upped their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 price objective on Twist Bioscience in a report on Tuesday, February 3rd. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $45.88.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.